Aggregate hedge fund holdings in Pfizer, concentrated across 11 funds, have fallen by roughly 1.6%.

Oncology revenues grew more than 7% in the first nine months of 2025, accounting for over 27% of overall sales. Revenue for the upcoming quarter is forecast at $16.84 billion (down 5.2% year-over-year) with EPS of $0.58 (down 7.9%). Pfizer secured a non-exclusive license to Novavax’s Matrix-M adjuvant with a $30 million upfront payment plus milestone and mid-single-digit royalty commitments, bolstering its vaccine pipeline. Management intends to maintain and grow the dividend over time.

Multiple patent expirations in the 2026–2030 window across blockbusters like Eliquis, Ibrance, Xeljanz and Xtandi coincide with declining COVID vaccine and treatment revenues, tighter U.S. drug-pricing rules and reduced pediatric immunization recommendations. Licensing deals for Matrix-M adjuvant, bispecific antibodies, GLP-1 drugs and weight-loss compounds; joint-venture restructurings; acquisitions; and multi-party R&D consortia aim to replenish the portfolio. Expansions in anticoagulant offerings and entrenched heparin producers add competitive pressure.

Enthusiasm for a long-term turnaround driven by oncology, obesity and late‐stage pipeline readouts is tempered by skepticism over patent expiries, stretched dividend coverage and near‐term revenue deceleration. Valuation narratives range from DCF-based undervaluation to doubts over market pricing and dividend safety, yet investors generally expect cost cuts, restructuring and new drug approvals to eventually restore growth, even as the timing of that recovery varies.